TY - JOUR
T1 - Role of Intraoperative Ultrasound to Extend the Application of Minimally Invasive Surgery for Treatment of Recurrent Gynecologic Cancer
AU - Mascilini, Floriana
AU - Quagliozzi, Lorena
AU - Moro, Francesca
AU - Moruzzi, Maria Cristina
AU - Gallotta, Valerio
AU - Gueli Alletti, Salvatore
AU - Scambia, Giovanni
AU - Testa, Antonia Carla
AU - Fagotti, Anna
PY - 2018
Y1 - 2018
N2 - STUDY OBJECTIVE:
To describe the potential role of intraoperative ultrasound (IOUS) in the detection and localization of recurrent disease in gynecologic cancer patients during minimally invasive surgery (MIS).
DESIGN:
A prospective cohort study (Canadian Task Force classification II-1).
SETTING:
A university hospital.
PATIENTS:
Fifty-one gynecologic cancer patients with isolated recurrent disease.
INTERVENTIONS:
IOUS during secondary cytoreductive surgery (SCS) by MIS.
MEASUREMENTS AND MAIN RESULTS:
From November 2015 to February 2017 51 gynecologic cancer patients with isolated recurrent disease and candidates for SCS were treated by MIS. Recurrent tumor was preoperatively assessed at clinical examination, transvaginal and transabdominal sonography, and radiologic evaluation in all women. Twelve of 51 women (23.5%) needed IOUS. Type of disease was ovarian in 5 women (42%), endometrial in 4 (33%), cervical in 1 (8%), vaginal cancer in 1 (8%), and uterine sarcoma in 1 (8%). Recurrence was localized deep in the pelvis in 7 cases (58%), lymph nodes in 3 (25%), and extraperitoneal in 2 cases (17%). Recurrence was dimmed in the surgical field, due to either presence of adherences, deep anatomic position, small size, and/or lack of tactile feeling. IOUS was able to identify the lesions in all women, allowing MIS (83% laparoscopy and 17% robotic) complete cytoreduction, with no conversion to laparotomy. Median operative time was 150 minutes (range, 77-280). No intraoperative/postoperative complications occurred. Histologic examination confirmed the presence of recurrence in 11 of 12 cases (92%), whereas the remaining case showed inflammatory tissue. With a median follow-up time of 15 months (range, 6-19), all patients except 2 were still alive.
CONCLUSIONS:
About 1 of 4 patients (25%) with single gynecologic cancer recurrence needs IOUS to benefit from MIS for complete secondary cytoreduction.
AB - STUDY OBJECTIVE:
To describe the potential role of intraoperative ultrasound (IOUS) in the detection and localization of recurrent disease in gynecologic cancer patients during minimally invasive surgery (MIS).
DESIGN:
A prospective cohort study (Canadian Task Force classification II-1).
SETTING:
A university hospital.
PATIENTS:
Fifty-one gynecologic cancer patients with isolated recurrent disease.
INTERVENTIONS:
IOUS during secondary cytoreductive surgery (SCS) by MIS.
MEASUREMENTS AND MAIN RESULTS:
From November 2015 to February 2017 51 gynecologic cancer patients with isolated recurrent disease and candidates for SCS were treated by MIS. Recurrent tumor was preoperatively assessed at clinical examination, transvaginal and transabdominal sonography, and radiologic evaluation in all women. Twelve of 51 women (23.5%) needed IOUS. Type of disease was ovarian in 5 women (42%), endometrial in 4 (33%), cervical in 1 (8%), vaginal cancer in 1 (8%), and uterine sarcoma in 1 (8%). Recurrence was localized deep in the pelvis in 7 cases (58%), lymph nodes in 3 (25%), and extraperitoneal in 2 cases (17%). Recurrence was dimmed in the surgical field, due to either presence of adherences, deep anatomic position, small size, and/or lack of tactile feeling. IOUS was able to identify the lesions in all women, allowing MIS (83% laparoscopy and 17% robotic) complete cytoreduction, with no conversion to laparotomy. Median operative time was 150 minutes (range, 77-280). No intraoperative/postoperative complications occurred. Histologic examination confirmed the presence of recurrence in 11 of 12 cases (92%), whereas the remaining case showed inflammatory tissue. With a median follow-up time of 15 months (range, 6-19), all patients except 2 were still alive.
CONCLUSIONS:
About 1 of 4 patients (25%) with single gynecologic cancer recurrence needs IOUS to benefit from MIS for complete secondary cytoreduction.
KW - Cancer
KW - Gynecology
KW - Minimally invasive surgery
KW - Recurrence
KW - Relapse
KW - Ultrasound
KW - Cancer
KW - Gynecology
KW - Minimally invasive surgery
KW - Recurrence
KW - Relapse
KW - Ultrasound
UR - http://hdl.handle.net/10807/113907
U2 - 10.1016/j.jmig.2017.12.023
DO - 10.1016/j.jmig.2017.12.023
M3 - Article
SN - 1553-4650
SP - 30001
EP - 30003
JO - Journal of Minimally Invasive Gynecology
JF - Journal of Minimally Invasive Gynecology
ER -